Antiemetic therapy and nausea management are critical components of supportive care in oncology, directly impacting patient comfort, treatment adherence, and quality of life. This blog presents focused multiple-choice questions tailored for M.Pharm students to deepen understanding of pathophysiology, receptor pharmacology, guideline-based prophylaxis, and practical drug selection for acute, delayed, anticipatory, and breakthrough chemotherapy-induced nausea and vomiting (CINV). The questions emphasize mechanisms of action, combination regimens (5-HT3 RAs, NK1 RAs, corticosteroids, olanzapine), adverse effects, drug interactions, and special situations like multiday chemotherapy or opioid-induced nausea. Use these MCQs to refine clinical reasoning and prepare for examinations in Pharmacotherapeutics II.
Q1. Which neurotransmitter and receptor are primarily responsible for acute chemotherapy-induced nausea and vomiting?
- Histamine acting at H1 receptors
- Dopamine acting at D2 receptors
- Serotonin acting at 5-HT3 receptors
- Substance P acting at NK1 receptors
Correct Answer: Serotonin acting at 5-HT3 receptors
Q2. Which drug class is most effective as first-line prophylaxis for acute CINV?
- Neurokinin-1 (NK1) receptor antagonists
- 5-HT3 receptor antagonists (e.g., ondansetron)
- Cannabinoid receptor agonists (e.g., dronabinol)
- Benzodiazepines (e.g., lorazepam)
Correct Answer: 5-HT3 receptor antagonists (e.g., ondansetron)
Q3. What is the primary mechanism of action of NK1 receptor antagonists like aprepitant in CINV?
- Blockade of dopamine D2 receptors in the chemoreceptor trigger zone
- Central GABA-A receptor potentiation to reduce anxiety-related nausea
- Blockade of substance P at neurokinin-1 (NK1) receptors
- Peripheral motility enhancement via muscarinic receptor agonism
Correct Answer: Blockade of substance P at neurokinin-1 (NK1) receptors
Q4. Which single agent is most commonly used to prevent delayed CINV?
- Ondansetron
- Dexamethasone
- Metoclopramide
- Diphenhydramine
Correct Answer: Dexamethasone
Q5. For highly emetogenic chemotherapy, which combination is recommended by guidelines for prophylaxis?
- Ondansetron alone
- NK1 RA + dopamine antagonist
- 5-HT3 RA + NK1 RA + dexamethasone (with/without olanzapine)
- Cannabinoid + benzodiazepine
Correct Answer: 5-HT3 RA + NK1 RA + dexamethasone (with/without olanzapine)
Q6. How does olanzapine contribute to control of refractory or highly emetogenic CINV?
- Selective 5-HT3 antagonism only
- Peripheral opioid receptor blockade
- Antagonism at multiple receptors including dopamine, serotonin (5-HT2/3), histamine and muscarinic receptors
- Pure cannabinoid receptor agonism
Correct Answer: Antagonism at multiple receptors including dopamine, serotonin (5-HT2/3), histamine and muscarinic receptors
Q7. What is the principal pharmacologic action of metoclopramide relevant to antiemetic therapy?
- 5-HT3 receptor antagonism only
- Central dopamine D2 receptor antagonism and prokinetic 5-HT4 agonist activity
- NK1 receptor antagonism
- GABA-B receptor agonism
Correct Answer: Central dopamine D2 receptor antagonism and prokinetic 5-HT4 agonist activity
Q8. Dronabinol and nabilone exert antiemetic effects primarily through which mechanism?
- 5-HT3 receptor antagonism in the gut
- Agonism of central cannabinoid CB1 receptors
- Blockade of peripheral substance P
- Muscarinic receptor antagonism in the vestibular system
Correct Answer: Agonism of central cannabinoid CB1 receptors
Q9. Which significant cardiac adverse effect is associated with many 5-HT3 receptor antagonists and requires monitoring?
- Torsades de pointes due to QT interval prolongation
- Marked hypertension
- Ventricular fibrillation unrelated to QT
- Atrioventricular block without QT changes
Correct Answer: Torsades de pointes due to QT interval prolongation
Q10. Which medication is most useful for anticipatory nausea related to prior chemotherapy sessions?
- Olanzapine
- Lorazepam
- Aprepitant
- Ondansetron
Correct Answer: Lorazepam
Q11. For breakthrough CINV despite prophylaxis, what is the recommended initial strategy?
- Switch to the same class used for prophylaxis at a higher dose
- Use a rescue agent from a different pharmacologic class, e.g., metoclopramide or haloperidol
- Stop all antiemetics and observe
- Only increase fluids without pharmacologic therapy
Correct Answer: Use a rescue agent from a different pharmacologic class, e.g., metoclopramide or haloperidol
Q12. How is “highly emetogenic” chemotherapy defined in terms of risk of emesis without prophylaxis?
- 10–30% risk of emesis
- 30–60% risk of emesis
- 60–90% risk of emesis
- >90% risk of emesis without prophylaxis
Correct Answer: >90% risk of emesis without prophylaxis
Q13. When added to a 5-HT3 antagonist and dexamethasone, what benefit does an NK1 receptor antagonist provide?
- Reduces only anticipatory nausea
- Improves prevention of delayed CINV when added to 5-HT3 RA and dexamethasone
- Increases prokinetic activity in the gut
- Replaces the need for dexamethasone entirely
Correct Answer: Improves prevention of delayed CINV when added to 5-HT3 RA and dexamethasone
Q14. Which antiemetic class is most commonly associated with extrapyramidal symptoms (EPS)?
- 5-HT3 receptor antagonists
- Dopamine D2 receptor antagonists such as metoclopramide
- Cannabinoids
- Benzodiazepines
Correct Answer: Dopamine D2 receptor antagonists such as metoclopramide
Q15. Selective 5-HT3 receptor antagonists are generally least effective for which type of nausea?
- Chemotherapy-induced nausea
- Postoperative nausea and vomiting
- Motion sickness (vestibular-mediated nausea)
- Acute CINV from cisplatin
Correct Answer: Motion sickness (vestibular-mediated nausea)
Q16. Which clinically important drug interaction is associated with aprepitant?
- Strong inhibition of CYP2D6 causing QT prolongation
- Moderate CYP3A4 inhibition leading to interaction with dexamethasone and some chemotherapy agents
- Complete inhibition of P-glycoprotein increasing all opioid levels
- No significant interactions due to inert metabolism
Correct Answer: Moderate CYP3A4 inhibition leading to interaction with dexamethasone and some chemotherapy agents
Q17. Which antiemetic also has appetite-stimulating properties and may be considered in cachectic oncology patients?
- Ondansetron
- Dronabinol (synthetic THC)
- Metoclopramide
- Prochlorperazine
Correct Answer: Dronabinol (synthetic THC)
Q18. In which clinical scenario is metoclopramide contraindicated or used with extreme caution?
- Functional dyspepsia without obstruction
- Mechanical bowel obstruction
- Postoperative ileus with clear evidence of obstruction
- Migraine-associated nausea
Correct Answer: Mechanical bowel obstruction
Q19. What is the most appropriate class of antiemetic for opioid-induced nausea in a cancer patient?
- 5-HT3 antagonists as first-line for opioid-related nausea
- Dopamine D2 receptor antagonists (e.g., metoclopramide)
- NK1 receptor antagonists exclusively
- Topical anticholinergics
Correct Answer: Dopamine D2 receptor antagonists (e.g., metoclopramide)
Q20. What is the preferred prophylactic approach for multiday moderately emetogenic chemotherapy?
- Single pre-treatment dose of 5-HT3 RA only on day 1
- Daily dosing of 5-HT3 RA plus dexamethasone on each day of chemotherapy; consider adding NK1 RA for high risk
- Only as-needed rescue antiemetics without scheduled prophylaxis
- Use cannabinoids alone throughout therapy
Correct Answer: Daily dosing of 5-HT3 RA plus dexamethasone on each day of chemotherapy; consider adding NK1 RA for high risk

I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com

